The Moses H. Cone Memorial Hospital
- Type
- Teaching hospital
- Where
- GREENSBORO, NC
- Medicare CCN
- 340091
- Received
- $2,158,833 in 546 records, 2020 ($115,988 general, $2,042,844 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: MOSES H CONE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 217 | $115,988 |
| 2020 | Research payment | 329 | $2,042,844 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 329 | $2,042,844 |
| Grant | 2 | $92,433 |
| Space rental or facility fees (teaching hospital only) | 13 | $10,700 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 20 | $8,000 |
| Gift | 179 | $4,022 |
| Consulting Fee | 2 | $790 |
| Charitable Contribution | 1 | $42 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Medtronic Vascular, Inc. | $6,687 | Research payment | In-kind items and services | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $42 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $32 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-12-29 | Amgen Inc. | $4,620 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $725 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-23 | Esperion Therapeutics, Inc. | $75 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-17 | CSL Behring | $123 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-16 | LivaNova USA, Inc. | $9,750 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2020 |
| 2020-12-15 | CSL Behring | $35,220 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | CSL Behring | $1,350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-11 | Esperion Therapeutics, Inc. | $36 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-10 | Aesculap, Inc. | $1,697 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,179 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,140 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-12-09 | Esperion Therapeutics, Inc. | $40 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-07 | Baxter Healthcare | $3,369 | Research payment | Cash or cash equivalent | Fluid Systems - Research Devel Biological, Fluid Systems | Peripheral IntraVenous Analysis -PIVA- compared with intermittent pulmonary capillary wedge pressure -PCWP-- in patients | 2020 |
| 2020-12-03 | SANOFI PASTEUR INC. | $16,100 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-12-02 | LivaNova USA, Inc. | $1,300 | Research payment | Cash or cash equivalent | VNS Therapy Device, Cardiology/Vascular Diseases | ANTHEM HFrEF | 2020 |
| 2020-11-24 | Varian Medical Systems, Inc. | $1,742 | Research payment | Cash or cash equivalent | Rapid Arc Device, Devices | Auto-Segmentation - Cone Health | 2020 |
| 2020-11-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-23 | Genentech, Inc. | $1,421 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-11-19 | CSL Behring | $689 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-19 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,450 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,358 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-11-12 | CSL Behring | $32,912 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-12 | CSL Behring | $1,350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-12 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-11-09 | Medtronic Vascular, Inc. | $156 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2020 |
| 2020-11-09 | Medtronic Vascular, Inc. | $156 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2020 |
| 2020-11-04 | Abbott Laboratories | $414 | Research payment | Cash or cash equivalent | Amplatzer PFO Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER PFO Occluder Post Approval Study | 2020 |
| 2020-11-04 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-02 | Esperion Therapeutics, Inc. | $107 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-28 | Abbott Laboratories | $6,978 | Research payment | Cash or cash equivalent | Nanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart Failure | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2020 |
| 2020-10-28 | CVRx, Inc. | $6,649 | Research payment | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2020 | |
| 2020-10-28 | Abbott Laboratories | $975 | Research payment | Cash or cash equivalent | Xience V Coronary Stent System Device, Cardiac Arrhythmias and Heart Failure | XIENCE 28 USA Study | 2020 |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-27 | CSL Behring | $123 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-24 | Amgen Inc. | $14,360 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | 2020 |
| 2020-10-22 | Surmodics, Inc. | $1,390 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2020 |
| 2020-10-22 | Surmodics, Inc. | $1,390 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $691 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-19 | AstraZeneca UK Limited | $10,350 | Research payment | Cash or cash equivalent | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-14 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-10-13 | Medtronic Vascular, Inc. | $334 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Resolute Device, Stents | 2020 | |
| 2020-10-13 | Medtronic Vascular, Inc. | $333 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Resolute Device, Stents | 2020 | |
| 2020-10-13 | Medtronic Vascular, Inc. | $333 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Resolute Device, Stents | 2020 | |
| 2020-10-09 | Amgen Inc. | $925 | Research payment | In-kind items and services | Repatha Biological, Cardiology | Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | 2020 |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $3,143 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-10-07 | Varian Medical Systems, Inc. | $200 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-10-06 | CSL Behring | $17,711 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-06 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-01 | Genentech, Inc. | $1,453 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2020 | |
| 2020-09-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-09-29 | Siemens Medical Solutions USA, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SOMATOM GO Device, CT and RO incl. Computed Tomography and Radiation Oncology | 2020 | |
| 2020-09-24 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $691 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-23 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $406 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $343 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $281 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $225 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | Esperion Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-22 | BIOTRONIK INC. | $44 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-V | 2020 |
| 2020-09-18 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-18 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2020 |
| 2020-09-17 | Medtronic Vascular, Inc. | $2,490 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Stroke AF | 2020 |
| 2020-09-14 | Becton, Dickinson and Company | $590 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-09-10 | CSL Behring | $39,618 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-09 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 |
The latest 200 records of 546.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Greensboro, NC | County Guilford County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 301,198 | 547,940 | 10,730,404 |
| Population, 2020 census P1 | 299,035 | 541,299 | 10,439,388 |
| Median age B01002 | 34.3 | 37.5 | 39.1 |
| Under 18 B01001 | 21.7% | 22.0% | 21.8% |
| 65 and over B01001 | 14.4% | 15.9% | 17.2% |
| Households B11001 | 123,984 | 219,718 | 4,282,345 |
| Foreign born B05002 | 12.7% | 11.8% | 9.1% |
| Median household income B19013 | $61,515 | $68,642 | $72,388 |
| Median family income B19113 | $80,585 | $88,156 | $90,290 |
| Per capita income B19301 | $37,531 | $39,376 | $41,385 |
| Poverty rate B17001 | 17.0% | 14.6% | 13.0% |
| Unemployment rate B23025 | 5.1% | 4.6% | 4.7% |
| Civilian labor force B23025 | 158,568 | 282,362 | 5,336,863 |
| Mean commute (minutes) B08013 | 21.7 | 22.0 | 25.1 |
| Bachelor's degree or higher B15003 | 41.0% | 39.0% | 35.7% |
| Housing units B25001 | 135,665 | 238,032 | 4,895,668 |
| Owner-occupied B25003 | 50.5% | 59.9% | 66.6% |
| Renters B25003 | 49.5% | 40.1% | 33.4% |
| Median home value B25077 | $244,800 | $259,900 | $288,900 |
| Median gross rent B25064 | $1,172 | $1,163 | $1,228 |
| White, not Hispanic B03002 | 38.1% | 46.0% | 60.0% |
| Black B03002 | 41.0% | 33.5% | 20.0% |
| Hispanic or Latino B03002 | 10.5% | 10.1% | 11.3% |
| Asian B03002 | 5.2% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.
Comments